Claudia Wagner, Ph.D.

Vice President TCR Research

TCR Discovery & TCR Delivery and Validation

Claudia joined Immatics in 2012. She is a passionate leader in cancer research, dedicating her career to harnessing the power of the immune system to combat diseases. Claudia is a part of the Discovery Unit leadership team at Immatics, shaping research and innovation.

In her role, she focuses on the development of novel T-cell receptor (TCR) based immunotherapies for cancer treatment. She is responsible for TCR discovery on the XCEPTOR® platform. With multiple teams in her two departments "TCR Delivery and Validation", she covers platform development, TCR identification and characterization, cell engineering approaches for adoptive cell therapy as well as IND-enabling efficacy and safety studies.

Claudia holds an M.Sc. in Biomedicine and a Ph.D. in Immunology from the Karolinska Institute, Sweden and completed a postdoctoral training in Immunobiology at Yale University, USA.